NSI-189 Cas No.1270138-40-3
- CasNo：1270138-40-3
- Molecular Formula：C22H30N4O
- Purity：
- Molecular Weight：
Product Details
|
1270138-40-3 Name |
|
|
Name |
NSI-189 |
|
Synonym |
NSI-189;(4-BENZYLPIPERAZIN-1-YL)-[2-(3-METHYLBUTYLAMINO)PYRIDIN-3-YL]METHANONE;(4-BENZYLPIPERAZIN-1-YL)(2-(ISOPENTYLAMINO)PYRIDIN-3-YL)METHANONE;[2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone;[2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone NSI189;NSI-189 [2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone;NSI-189, >=98%;(4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl] |
|
1270138-40-3 Biological Activity |
|
|
Description |
NSI-189 is a nootropic and neurogenic research chemical derived from nicotinamide and pyrazine.IC50 value:Target: in vitro: NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. The hippocampus is responsible for the consolidation of information from short-term memory to long-term memory, along with spatial navigation [1] [2].in vivo: NSI-189 has been shown to increase the hippocampal volume of healthy adult mice by 20% [3]. |
|
Related Catalog |
Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease |
|
References |
[1]. http://gizmodo.com/5874433/the-pill-that-could-cure-depression-by-growing-your-brain [2]. Compositions to effect neuronal growth US 8030492 B2 [3]. Why Neuralstem Could Provide A 10x Return |
|
1270138-40-3 Chemical & Physical Properties |
|
|
Boiling point |
534.7±50.0 °C at 760 mmHg |
|
Density |
1.1±0.1 g/cm3 |
|
Molecular Formula |
C22H30N4O |
|
Molecular Weight |
366.500 |
|
Flash Point |
277.2±30.1 °C |
|
PSA |
48.47000 |
|
LogP |
4.13 |
|
Exact Mass |
366.241974 |
|
Vapour Pressure |
0.0±1.4 mmHg at 25°C |
|
Index of Refraction |
1.601 |
|
1270138-40-3 Description |
|
NSI-189 is an investigational drug being developed by Neuralstem Inc., a biopharmaceutical company. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke. NSI-189 was studied in phase I and II clinical trials for the treatment of major depressive disorder. As of July 2017, NSI-189 has failed to meet effectiveness outcomes for depression in phase II trials. |
|
1270138-40-3 Uses |
|
NSI-189 is an experimental, potential antidepressant, for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration. |
